Clinical trials Herbamuno+ as adjuvants handling of Covid-19 is targeted to be completed in a matter of months. With the completion of clinical trials, the status of Herbamuno as herbal medicine will be increased to pharmacy or medicine made from herbs.
“The target of clinical trials completed in a matter of months in this year. Clinical trials will improve the Herbamuno ready to become a pharmacy as an adjuvant drug Covid-19,” said Director of Business Development and Innovation of PT Mustika Ratu Tbk Kusuma Ida Anjani to Investor Daily during a media visit to the BeritaSatu Media Holdings, on Tuesday (25/1/2022).
Clinical trials Herbamuno+ co-chaired by lungs experts of RS Wisma Atlet Kemayoran, Jakarta, and also cooperate with the University of Indonesia.
Herbamuno+ is made from a combination of 5 Indonesian herbs, which are Andrographis paniculatae, Zingiberis Officinalis Rhizoma, Phyllanthus niruri, licorice, and cashew leaf. Sambiloto which is famous for having a bitter taste is useful as antiviral, anti-inflammatory, anti-pain, and fever.
Phyllanthus niruri is efficacious as a regulator of the body’s immune or immunomodulators and nourishes the liver (hepatoprotector). Licorice is efficacious as an antiviral, anti-inflammatory, anti-pain, relieves cough with phlegm (eksprektoran), and relieves shortness of breath.
Zingiberis Officinalis Rhizoma is efficacious to overcome nausea, vomiting as well as immunomodulatory and nourish the digestive (gastroprotector). The cashew leaves are efficacious as anti-pain, relieve diarrhea, and respiratory relief (bronchodilator).
“The combination of five herbal ingredients this nutritious help to improve endurance, relieve symptoms of Covid-19 such as fever, dizziness, pain, diarrhea, bloating, and relieve the stone as well as shortness of breath,” said Kusuma Ida Anjani.***